title: Randomized controlled trial comparing somatostatin with octreotide in the prevention of complications after pancreatectomy.
abstract: OBJECTIVE
  The postoperative morbidity following pancreaticoduodenectomy (PD) remains very high. Somatostatin or octreotide are indicated in the prevention of pancreatic stump-related complications. The aim of this study is to compare the efficacy of somatostatin and octreotide after PD.
  
  
  METHODS
  Between November 2000 and December 2003 we collected prospectively clinical and biological data from patients with a benign or malignant pancreatic tumor requiring a PD. Fifty patients were randomized into two groups, 25 treated with somatostatin (group S) and 25 with octreotide (group O).
  
  
  RESULTS
  There was no postoperative death. Complications occurred in 20 patients (40%), 11 in group S, 9 in group O (NS). General complications occurred in 7 patients in group S, and 5 patients in group O. Local complications related to the pancreatic stump were found in 4 patients in both groups. At the end of the period of administration of the two study drugs, 2 patients (8%) had a pancreatic fistula in group S and 3 in group O (12%) (p=0.52). A trend of more rapid decreased level of amylase and lipase concentrations in surgical drainage was observed in group S but it is not statistically significant (p=0.29).
  
  
  CONCLUSIONS
  In patients requiring PD for pancreatic tumor, somatostatin and octreotide seem to behave similarly in the postoperative period.
authors.affiliation: Medicosurgical Department of Hepatogastroenterology, ULB Erasme Hospital, Route de Lennik 808, 1070 Brussels, Belgium. jclosset@ulb.ac.be
authors.forename: Jean
authors.initials: J
authors.lastname: Closset
authors.forename: Stephane
authors.initials: S
authors.lastname: Journe
authors.forename: Freddy
authors.initials: F
authors.lastname: Mboti
authors.forename: Issam
authors.initials: I
authors.lastname: El Nakadi
authors.forename: Michel
authors.initials: M
authors.lastname: Gelin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D016577:Pancreaticoduodenectomy / Q000009:adverse effects*; D011183:Postoperative Complications / Q000188:drug therapy*; D013004:Somatostatin / Q000627:therapeutic use*
chemical_list: D013004:Somatostatin; D015282:Octreotide